Abstract: The invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparing a medicament for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.

Abstract: The present invention relates to substituted arylsulphonylaminomethyl-phosphonic acid derivatives of general formula wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

Abstract: The present invention relates to substituted arylsulphonylaminomethyl-phosphonic acid derivatives of general formula wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

Abstract: The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

Abstract: The present invention relates to substituted arylsulphonylglycines of general formula wherein R, R4, X, Y, Z and m are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

Abstract: The present invention relates to a novel compound of the formula I: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-? converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.

Abstract: The present invention relates to a novel compound of the formula I: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-? converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.

Abstract: The present invention involves substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are defined herein. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds and methods for the treatment of metabolic disorders such as type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerosis diseases and the like through the administration of said compositions.

Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula l: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.

Abstract: A method for drying laundry in a laundry dryer having a program control device, a drying chamber and a process air circuit includes providing a flow dividing device in the process air circuit for dividing the drying air flow into an exhaust air component and a recirculated air component. A sensor is used to measure a pressure in the process air stream in an area where the drying air enters the drying chamber. The pressure is evaluated and the flow dividing device is controlled based on the evaluation so as to reduce or set to zero the recirculated air component and to continue the drying process at a reduced volumetric flow rate of the drying air through the drying chamber.

Abstract: The invention relates to compounds of the formula I in which the radicals have the meanings stated in the text, their stereoisomeric forms, and their physiologically tolerated salts, physiologically functional derivatives and process for their preparation. The compounds are suitable for the treatment of disorders of metabolism, such as type 2 diabetes.

Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, their stereoisomeric forms and their physiologically tolerated salts and process for their preparation. The compounds are suitable for the treatment of metabohlic disorders such as type 2 diabetes.

Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, their stereoisomeric forms and their physiologically tolerated salts and process for their preparation. The compounds are suitable for the treatment of metabohlic disorders such as type 2 diabetes.

Abstract: The invention relates to compounds of the formula I in which the radicals have the meanings stated in the text, their stereoisomeric forms, and their physiologically tolerated salts, physiologically functional derivatives and process for their preparation. The compounds are suitable for the treatment of disorders of metabolism, such as type 2 diabetes.

Abstract: A solenoid valve achieves high reliability and small size with fine tolerance. The solenoid valve having a valve housing, an electromagnet composed of a coil, a yoke and a clapper armature having at least a first valve seat, and a sealing element which can be actuated by the clapper armature and which co-operates with the first valve seat. The yoke has yoke pins and the clapper armature is magnetically and pivotally connecting with one of the yoke pins at the end thereof that is remote from the sealing element. The clapper armature is guided through the coil.

Abstract: A cylinder head for a direct-injection spark-ignition internal combustion engine includes, for each cylinder, an inlet valve, an exhaust valve, a first receptacle, a second receptacle, and a third receptacle. The first, second, and third receptacles are respectively configured to receive an ignition device or an injection device. The first receptacle extends substantially parallel to the inlet valve. The second receptacle extends substantially parallel to the exhaust valve. A common camshaft is offset from a cylinder center plane and actuates the inlet valve and the exhaust valve via identically constructed valve actuating elements. The cylinder head is lightweight, compact and easy to assemble and is in particular suited for high performance engines.

Abstract: A cylinder head for a direct-injection spark-ignition internal combustion engine includes, for each cylinder, an inlet valve, an exhaust valve, a first receptacle, a second receptacle, and a third receptacle. The first, second, and third receptacles are respectively configured to receive an ignition device or an injection device. The first receptacle extends substantially parallel to the inlet valve. The second receptacle extends substantially parallel to the exhaust valve. A common camshaft is offset from a cylinder center plane and actuates the inlet valve and the exhaust valve via identically constructed valve actuating elements. The cylinder head is lightweight, compact and easy to assemble and is in particular suited for high performance engines.

Abstract: The invention relates to a solenoid valve having a valve housing, an electromagnet, which has a coil, a yoke and a clapper armature, and having at least a first valve seat and a sealing element which can be actuated by the clapper armature and which co-operates with the first valve seat. The yoke has yoke pins and the clapper armature is arranged on a yoke pin at the end thereof that is remote from the sealing element.

Abstract: The pressure-reducing valve according to the invention makes available at its secondary pressure connection a generally adjustable secondary or working pressure which can be used by connected compressed-air consumers. The pressure-reducing valve provides a constant working pressure irrespective of fluctuations in the primary pressure or in the consumption of compressed air by the compressed air consumers. In the pressure-reducing valve according to the invention, a second pressure chamber in the central region of the slide is exposed to the primary pressure via a primary pressure connection. First and third pressure chambers at the end regions of the slide are, on the other hand, exposed to the secondary pressure via a secondary pressure connection. In addition, third and fourth chambers are connected to one another by way of a third connecting duct.

Abstract: The invention relates to a pressure-reducing valve having